

令和 5(2023)年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	秋田智之、田中純子	日本におけるC型肝炎の疫学—国際比較—		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	91-99	○
2)	相崎英樹、溝上雅史、脇田隆字	ウイルス性肝炎発見の歴史		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	7-11	
3)	保坂哲也	核酸アナログ製剤治療による HBs 抗原陰性化と発癌		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	345	○
4)	保坂哲也	発癌高リスク群の設定、B型慢性肝炎	佐藤雅哉	臨床検査 10 月・増大号「肝疾患臨床検査でどう迫る？」	医学書院	東京	2023	1122	○
5)	保坂哲也	B型慢性肝炎の薬物療法	臨床消化器内科編集委員会	臨床消化器内科 6 月増刊号「肝疾患、診療のチェックポイント 2023」	日本メディカルセンター	東京	2023	160	○
6)	菊地勘	透析医療における標準的な透析操作と感染予防に関するガイドライン（六訂版）	日本透析医会	透析医療における標準的な透析操作と感染予防に関するガイドライン（六訂版）	日本透析医会	東京	2023	1-146	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Okada K, Nakayama Y, s Xu J, Cheng Y, <u>Tanaka J</u>	A nation-wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	Hepatology Research			in press	
2)	Kimura M, Nishikawa T, Shimakami T, Terashima T, Horii R, Fukuda M, Yoshita M, Takata N, Hayashi T, Funaki M, Nio K, Takatori H, Arai K, Yamashita T, Honda M, <u>Tanaka J</u> , Kaneko S, Yamashita T	Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis	Global Health & Medicine			in press	○
3)	Kumada T, Toyoda H, Ogawa S, Gotoh T, Suzuki Y, Sugimoto K, Yoshida Y, Kuroda H, Kamada Y, Sumida Y, Ito T, Akita T, <u>Tanaka J</u>	Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease	Liver International			in press	○
4)	amaguchi D, Chimed-Ochir O, Yumiya Y, Kishita E, Akita T, <u>Tanaka J</u> , Kubo, T	Potential Risk Factors to COVID-19 Severity: Comparison of SARS-CoV-2 Delta- and Omicron-Dominant Periods	International Journal of Environmental Research and Public Health	21(3)	322	2024	
5)	Toyoda H, Koshiyama Y, Yasuda S, Kumada T, Chayama K, Akita T, <u>Tanaka J</u>	Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection	Journal of Viral Hepatitis	31(3)	137-142	2024	○
6)	Kurusu A, Sugiyama A, Akita T, Takumi I, Yamamoto H, Iida K, <u>Tanaka J</u>	Incidence and prevalence of epilepsy in Japan: a retrospective analysis of insurance claims data of 9,864,278 insured persons	Journal of epidemiology	34(2)	70-75	2024	
7)	Setoyama H, Nishida N, Nagashima S, Ko K, Yamazoe T, Tanaka Y, Mizokami M, <u>Tanaka J</u> , Kanto T	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52	1147-1155	2023	○
8)	Takemoto Y, Tanimine N, Yoshinaka H, Tanaka Y, Takafuta T, Sugiyama A, <u>Tanaka J</u> , Ohdan H	Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population	Frontiers in Immunology	14	1217206	2023	
9)	Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, Akita T, Kobayashi T, Hattori M, Hasunuma N, <u>Tanaka J</u> , Ohge H	Virtual reality as a learning tool for improving infection control procedures	American Journal of Infection Control	51(2)	129	2023	
10)	Ko K, Takahashi K, Ito N, Sugiyama A, Nagashima S, Miwata K, Kitahara Y, Okimoto M, Ouoba O, Golda Akuffo GA, E B, Akita T, Takafuta T, <u>Tanaka J</u>	Despite low viral titer in saliva samples, Sanger-based SARS-CoV-2 spike gene sequencing is highly applicable for the variant identification	BMC Medical Genomics	16(1)	199	2023	
11)	Saito E, Tanaka S, Abe S, Hirayabashi M, Ishihara J, Katanoda K, Lin Y, Nagata C, Sawada N, Takachi R, Goto A, Tanaka J, Ueda K, Hori M, Matsuda T, Inoue M	Economic burden of cancer attributable to modifiable risk factors in Japan	Global Health & Medicine	5(4)	238-245	2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	Hussain Md RA, Ali Mohammad, Sugiyama A, Hiebert L, Rahman M. A, Azam G, Ouoba S, E B, Ko K, Akita T, W. Ward J, <u>Tanaka J</u>	The impact of COVID-19 on hepatitis B and C virus prevention, diagnosis, and treatment in Bangladesh compared with Japan and the global perspective	BMC Health Services Research	23(1137)	1	2023	
13)	Ouoba S, Ko K, Lingani M, Nagashima S, Guingané A N , E Bunthen, Hussain Md RA , Sugiyama Aya, Akita T, Ohisa M, Sanou M A, Traore O, Nassa J W, Sanou M, Takahashi K, Halidou T, <u>Junko T</u>	Intermediate hepatitis B virus infection prevalence among 1622 pregnant women in rural Burkina Faso and implications for mother-to-child transmission	Scientific Reports	13(1)	6115	2023	○
14)	E Bunthen, Ko K, Kim R, Nagashima S, Ouoba S, Hussain Md RA, Sato T, Chuon C, Abe K, Sugiyama A, Takahashi K, Akita T, Tung R, Ork V, Hossain Md S, Saphonn V, Tanaka J	Residual risk of mother-to-child transmission of HBV despite timely Hepatitis B vaccination: a major challenge to eliminate hepatitis B infection in Cambodia	BMC	23(1)	261	2023	○
15)	Basirat Mojisola Lawal-Ayinde, Morita T, Oda K, Nazmul T, Kurose M, Nomura T, Yamamoto A, Higashiura A, Akita T, <u>Tanaka J</u> , Horiuchi I, Goda H, Sakaguchi T	Virus purification highlights the high susceptibility of SARS-CoV-2 to a chlorine-based disinfectant, chlorous acid.	PLOS ONE	18(7)	e0288634	2023	
16)	Polaris Observatory Collaborators Homie A. Razavi, Maria Buti, Norah A. Terrault, Stefan Zeuzem, Cihan Yurdaydin, <u>Junko Tanaka</u> , Alessio Aghemo, Ulus S. Akarca, Nasser M Al Masri, Abduljaleel M. Alalwan, Soo Aleman, Abdullah S. Alghamdi, Saad Alghamdi, Waleed K. Al-Hamoudi, Abdulrahman A. Aljumah, Ibrahim H. Altraif, Tarik Asselah, Ziv Ben-Ari, Thomas Berg, Mia J. Biondi, Sarah Blach, Wornei S.M. Braga, Carlos E. Brandão-Mello, Maurizia R. Brunetto, Joaquin Cabezas, Hugo Cheinquer, Pei-Jer Chen, Myeong-Eun Cheon, Wan-Long Chuang, Carla S. Coffin, Nicola Coppola, Antonio Craxi, Javier Crespo, Victor De Ledinghen, Ann-Sofi Duberg, Ohad Etzion, Maria Lucia G Ferraz, Paulo R.A. Ferreira, Xavier Forns, Graham R. Foster, Giovanni B. Gaeta, Ivane Gamkrelidze, Javier García-Samaniego, Liliana S. Gheorghe, Pierre M. Gholam, Robert G. Gish, Jeffrey Glenn, Julian Hercun, Yao-Chun Hsu, Ching-Chih Hu, Jee-Fu Huang, Naveed Janjua, Jidong Jia, Martin Käberg, Kelly D.E. Kaita, Habiba Kamal, Jia-Horng Kao, Loreta A. Kondili, Martin Lagging, Pablo Lázaro, Jeffrey V. Lazarus, Mei-Hsuan Lee, Young-Suk Lim, Paul J. Marotta, Maria-Cristina Navas, Marcelo C.M. Naveira, Mauricio Orrego, Carla Osiowy, Calvin Q. Pan, Mário G. Pessoa, Giovanni Raimondo, Alnoor Ramji, Devin M. Razavi-Shearer, Kathryn Razavi-Shearer, Cielo Y. Ríos-Hincapié, Manuel Rodríguez, William M.C. Rosenberg, Dominique M. Roulot, Stephen D. Ryder, Rifaat Safadi, Faisal M. Sanai, Teresa A. Santantonio, Christoph Sarrazin, Daniel Shouval, Frank Tacke, Tammo L. Tergast, Juan Miguel Villalobos-Salcedo, Alexis S. Voeller, Hwai-I Yang, Ming-Lung Yu, Eli Zuckerman	Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries	Journal of Hepatology	79(2)	576-580	2023	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
17)	Imada H, Akita T, Sugiyama A, <u>Tanaka J</u>	Trend of blood donors entering the coronavirus pandemic era and challenges: Age-Period-Cohort analysis using 75.5 million all blood donations data during 2006-2020 in Japan	Transfusion	63(6)	1184-1194	2023	
18)	Shimakami T, Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, <u>Tanaka J</u> , Kanto T	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan	Journal of gastroenterology	58(3)	257-267	2023	○
19)	Ichikawa H, Yasuda E, Kumada T, Takeshima K, Ogawa S, Tsunekawa A, Goto T, Nakaya K, Akita T, <u>Tanaka J</u>	Intra-individual comparison of liver stiffness measurements by magnetic resonance elastography and two-dimensional shear-wave elastography in 888 patients	Ultrasonography	42(1)	65-77	2023	○
20)	Maeshige N, Hayashi H, Terashi H, Fujii M, Iwamoto T, Watanabe Yu, Imaoka S, Matsumoto J, Nishikawa M, Takeda N, Mikawa R, Tsuji Y, Higashita R, Ayabe S, Terabe Y, Furukawa M, <u>Tanaka J</u> , Ohura T, Kawabe N	Effect of early rehabilitation on gait, wound and home discharge in lower extremity chronic wound patients: a Japanese multicenter retrospective study	The International Journal of Lower Extremity Wounds	22(4)	713-721	2023	
21)	Ko K, Phyo Z, Mirzaev U, <u>田中純子</u>	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	アグリバイオ	7(14)	93-101	2023	○
22)	杉山文、 <u>田中純子</u>	感染予防各論 肝炎ウイルス HB ワクチン	臨床透析	39(7)	133-141	2023	○
23)	<u>田中純子</u>	初回供血者および検診受検集団における HB s 抗原陽性率の状況	病原微生物検出情報 (月報)	44(3)	3-4	2023	○
24)	<u>田中純子</u> 、秋田智之、杉山文	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	アグリバイオ	7(4)	56-64	2023	○
25)	<u>Satake M</u> , Yamagishi N, Tanaka A, Goto N, Sakamoto T, Yanagino Y, Furuta RA, Matsubayashi K.	Transfusion-transmitted HBV infection with isolated anti-HBs-positive blood.	Transfusion	63(6)	1250-1254	2023	○
26)	Tanaka A, Yamagishi N, Hasegawa T, Miyakawa K, Goto N, Matsubayashi K, <u>Satake M</u> .	Marked reduction in the incidence of transfusion-transmitted hepatitis B virus infection after the introduction of antibody to hepatitis B core antigen and individual donation nucleic acid amplification screening in Japan.	Transfusion	63(11)	2083-2097	2023	○
27)	Fukano K, Wakae K, Nao N, Saito M, Tsubota A, Toyoshima T, <u>Aizaki H</u> , Iijima H, Matsudaira T, Kimura M, Watashi K, Sugiura W, Muramatsu M.	A versatile method to profile hepatitis B virus DNA integration.	Hepatol Commun.	7		2023	○
28)	shima M, Stappenbeck F, Ohashi H, Iwamoto M, Fukano K, Kusunoki A, Zheng X, Wang F, Morishita R, <u>Aizaki H</u> , Suzuki R, Muramatsu M, Kuramochi K, Sureau C, Parhami F, Watashi K.	Selective inhibition of hepatitis B virus internalization by oxysterol derivatives.	Biochem Biophys Res Commun.	675	139-145	2023	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
29)	Aoyagi H, Iijima H, Gaber ES, Zaitso T, Matsuda M, Wakae K, Watashi K, Suzuki R, Masaki T, Kahn J, Saito T, El-Kassas M, Shimada N, Kato K, Enomoto M, Hayashi K, Tsubota A, Mimata A, Sakamaki Y, Ichinose S, Muramatsu M, Wake K, Wakita T, <u>Aizaki H</u> .	Hepatocellular organellar abnormalities following elimination of hepatitis C virus.	Liver Int.	43	1677-1690	2023	○
30)	Uchida T, Imamura M, Hayes CN, Suehiro Y, Teraoka Y, Ohya K, Aikata H, Abe-Chayama H, Ishida Y, Tateno C, Hara Y, Hino K, Okamoto T, Matsuura Y, <u>Aizaki H</u> , Wake K, Kohara M, Liang TJ, Oka S, Chayama K.	HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.	Hepatology.	13		2023	○
31)	Fumitaka Suzuki, <u>Tetsuya Hosaka</u> , Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Satoshi Saitoh, Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada.	Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance	Journal of gastroenterology			in press	○
32)	Tai-Chung Tseng, <u>Tetsuya Hosaka</u> , Chun-Jen Liu, Fumitaka Suzuki, Chieh Chiang, Chun-Ming Hong, Hiromitsu Kumada, Wan-Ting Yang, Tung-Hung Su, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Jia-Horng Kao	HBcrAg-based risk score performs better than HBV DNA-based score for HCC prediction in HBeAg-negative grey zone patients	JHEP Reports			in press	○
33)	Norio Akuta, Hitomi Sezaki, Shunichiro Fujiyama, Yusuke Kawamura, <u>Tetsuya Hosaka</u> , Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada.	Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals	Oncology	101(2):	79-88.	2023	○
34)	Iwamoto H, Suzuki H, Masuda A, Sakaue T, Nakamura T, Tanaka T, Sakai M, Imamura Y, Yano H, Torimura T, <u>Koga H</u> , Yasuda K, Tsurusaki M, Seki T, Kawaguchi T.	A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.	iScience	27(2)	108797	2024	
35)	Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, Yano Y, Nakamura H, Itano S, Miyajima I, Shirachi M, Kuwahara R, Ohno M, Kawaguchi T, Tsutsumi T, Nakano D, Arinaga-Hino T, Kawaguchi M, Eguchi Y, <u>Torimura T</u> , Takahashi H, Harada M, Kawaguchi T; SAKS Study Group.	Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study.	Hepatol Res	(Nov 17)		2023	○
36)	Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, <u>Koga H</u> , Hoshida Y, Kawaguchi T.	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.	Hepatol Int	(Oct 21)		2023	
37)	Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, Noda Y, Nakano M, Suga H, Kuromatsu R, <u>Torimura T</u> , <u>Koga H</u> , Kawaguchi T.	Efficacy of lenvatinib combined with transcatheter intra-arterial therapies for patients with advanced-stage of hepatocellular carcinoma: a propensity score matching.	Int J Mol Sci	24(18)	13715	2023	
38)	Tanaka T, <u>Koga H</u> , Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T.	Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.	Hepatol Int	(Aug 8)		2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
39)	Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwara M, Itano S, Yano Y, Matsugaki S, Moriyama E, Noda Y, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancer Med	12(11)	12325-12335	2023	
40)	<u>Koga H</u> , Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T.	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Japanese perspective.	Clin Mol Hepatol	29(2)	242-251	2023	
41)	Tsumura S, Shimose S, Niizeki T, Kuboyama E, Iwamoto H, Tanaka M, Moriyama E, Shirono T, Takaki K, Noda Y, Nakano M, Inoue M, Tsustumi K, Kuromatsu R, <u>Koga H</u> , Higuchi K, Kawaguchi T.	Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.	J Gastroenterol Hepatol	38(7)	1140-1147	2023	
42)	Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.	Hepatol Res	53(2)	116-126	2023	
43)	Minami T, Sato M, <u>Toyoda H</u> , Yasuda S, Yamada T, Nakatsuka T, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Tanaka Y, Otsuka M, Ohki T, Arai M, Asaoka Y, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Nakagomi R, Akamatsu M, Mitsui H, Fujie H, Ogura K, Uchino K, Yoshida H, Hanajiri K, Wada T, Kurai K, Maekawa H, Kondo Y, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Yotsuyanagi H, Moriya K, Kumada T, Fujishiro M, Koike K, Tateishi R	Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.	J Hepatol			in press	○
44)	<u>Toyoda H</u> , Koshiyama Y, Yasuda S, Kumada T, Chayama K, Akita T, <u>Tanaka I</u>	Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection.	J Viral Hepat			in press	○
45)	Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, Solda C, Piscaglia F, Tosetti G, Marra F, Vivaldi C, Conti F, Schirripa M, Iwamoto H, Sho T, Lee SH, Rizzato MD, Tonnini M, Rimini M, Campani C, Masi G, Foschi FG, Bruccoleri M, Kawaguchi T, Kumada T, Hiraoka A, Atsukawa M, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Kawata K, Tada F, Ohama H, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Casadei-Gardini A, Lampertico P	Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib.	Liver Cancer			in press	
46)	Kariyama K, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kudo M, Kumada T	Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs ablation: a multicenter retrospective study.	J Liver Cancer			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
47)	Huang DQ, Hoang JK, Kamal R, Tsai PC, <u>Toyoda H</u> , Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Jun DW, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH	Antiviral therapy utilization and 10-year outcomes in resected HBV- and HCV-related hepatocellular carcinoma.	J Clin Oncol			in press	○
48)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T	A comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: a multicenter study.	Hepatol Res			in press	
49)	Arai T, Takahashi H, Seko Y, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanou T, Itoh Y, Nakajima A, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications.	Clin Gastroenterol Hepatol			in press	
50)	Park JE, Nguyen VH, Tsai PC, Toyoda H, Leong J, Dr. Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH	Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.	Aliment Pharmacol Ther			in press	
51)	<u>Toyoda H</u> , Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, Hiraoka A, Abe H, Itobayashi E, Matsuura K, Atsukawa M, Watanabe T, Shimada N, Nakamura M, Kojima M, Tsuji K, Mikami S, Ishikawa T, Yasuda S, Tsutsui A, Arai T, Kumada T, Tanaka Y, <u>Tanaka J</u> , Chayama K	Comparison of six HCC prediction models in Japanese patients after SVR undergoing rigorous surveillance for HCC.	J Gastroenterol Hepatol			in press	○
52)	Johnson PJ, Bhatti E, <u>Toyoda H</u> , He S	Serological detection of HCC in full-application of machine learning and implications for the diagnostic models.	JCO Clin Cancer Inform			in press	
53)	Johnson PJ, Kalyuzhnyy A, Boswell E, <u>Toyoda H</u>	Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management.	BJC Rep			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini	Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study.	Liver Cancer			in press	
55)	Ogawa S, Kumada T, Gotoh T, Niwa F, <u>Toyoda H</u> , Tanaka J, Shimizu M	A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on MRI-derived proton density fat fraction.	Hepatol Res			in press	
56)	Iwaki M, Fujii H, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study.	Clin Mol Hepatol			in press	
57)	Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, Ohama H, Nouse K, Matono T, Nakamura S, <u>Toyoda H</u>	mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.	J Gastroenterol Hepatol			in press	
58)	Kumada T, <u>Toyoda H</u> , Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J, Shimizu M	Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: a multicenter prospective study.	Hepatol Res			in press	
59)	Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Solda C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F	Impact of body mass index on the prognosis of unresectable HCC patients receiving first line lenvatinib or atezolizumab plus bevacizumab.	Liver Int			in press	



発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwaomto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, <u>Toyoda H</u> , Kanto T	Serum osteopontin as a predictive biomarker for the response to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.	J Gastroenterol			in press	
61)	Kumada T, <u>Toyoda H</u> , Ogawa S, Gotoh T, Suzuki Y, Imajo K, Sugimoto K, Kakegawa T, Kuroda H, Yasui Y, Tamaki N, Kurosaki M, Izumi N, Akita T, Tanaka J, Nakajima A	Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis.	Ultrasonography			in press	
62)	Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, Kam LY, Nguyen VH, Ogawa E, Lee DH, Ito T, Watanabe T, Enomoto M, Preda CM, Ko MKL, Hui RWH, Atsukawa M, Suzuki T, Marciano S, Barreira A, Do S, Uojima H, Takahashi H, Quek SXZ, Khine HHTW, Ishigami M, Itokawa N, Go MS, Kozuka R, Marin RI, Sandra I, Li J, Zhang JQ, Wong C, Yoshimaru Y, Vo DKH, Tseng CH, Lee CJ, Inoue K, Maeda M, Hoang JK, Chau A, Chuang WL, Dai CY, Huang JF, Huang CF, Buti M, Tanaka Y, Gadano AC, Yuen MF, Cheung R, Lim SG, Trinh HN, <u>Toyoda H</u> , Yu ML, Nguyen MH	Sex and ethnic disparities in hepatitis B evaluation and treatment: a real-world study from both East and West.	J Hepatol			in press	
63)	<u>Toyoda H</u> , Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Pinero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, Atsukawa M, Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ	Regional differences in clinical presentation and prognosis of patients with post-sustained virologic response (SVR) hepatocellular carcinoma.	Clin Gastroenterol Hepatol	22	72-80	2024	○
64)	<u>Toyoda H</u> , Kikuchi K	Author response to management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.	Ther Apher Dial	28	160-161	2024	○
65)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M	Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.	Liver Int	44	113-124	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
66)	Jang TY, Liang PC, Jun DW, Jung JH, <u>Toyoda H</u> , Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon E, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML	Pre-treatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.	Kaohsiung J Med Sci	40	188-197	2024	
67)	Ogawa E, Jun DW, <u>Toyoda H</u> , Hsu YC, Yoon EL, Ahn SB, Yeh ML, Do S, Trinh HM, Takahashi H, Enomoto M, Kawada N, Yasuda S, Tseng CH, Kawashima K, Lee HA, Inoue K, Haga H, Do AT, Maeda M, Hoang JH, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, Tanaka Y, Nguyen MH	Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: a prospective, multinational study.	Aliment Pharmacol Ther	59	239-248	2024	
68)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Int J Cancer	154	1043-1056	2024	
69)	Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A	Safety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinoma.	Target Oncol	19	29-39	2024	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
70) Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M	Does first-line treatment have prognostic impact for unresectable HCC? – atezolizumab plus bevacizumab vs. lenvatinib.	Cancer Med	12	325-334	2023	
71) Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano Y, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori K, Iijima H, Hiasa Y, Kumada T	Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: a Japanese multicenter observational study.	Cancer Med	12	5293-5303	2023	
72) Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, <u>Toyoda H</u> , Yasuda S, Naganuma A, T Tada, Takaguchi K, Tsutsui A, Itobayashi E, Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouse K, Kosaka H, Kaibori M, Kumada T	The prognosis of elderly patients with hepatocellular carcinoma: a multi-center 19-year experience in Japan.	Cancer Med	12	345-357	2023	
73) Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, Arai T, Atsukawa M, Yoon E, Tsai PC, <u>Toyoda H</u> , Huang JF, Henry L, Jun DW, Yu ML, Ishigami M, Nguyen MH, Cheung RC	Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients.	Clin Gastroenterol Hepatol	21	1013-1022	2023	
74) Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T.	Development and validation of a modified albumin-bilirubin grade and $\alpha$ -fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.	Hepatol Int	17	86-96	2023	
75) Lee CM, Yoon EL, Nakajima A, Yoneda M, <u>Toyoda H</u> , Yasuda S, Lee J, Kim M, Kang BK, Nguyen MH, Jun DW, Sumida Y	A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis.	Am J Gastroenterol	118	840-847	2023	
76) Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa H, Kumada T	The hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC-GRIm-Score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis.	Cancer Med	12	4259-4269	2023	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
77)	Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, <u>Toyoda H</u> , Taniai N, Yoshida H, Tanaka Y, Iwakiri K	Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: a retrospective, multicenter study.	Hepatol Res	53	51-60	2023	
78)	Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouse K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y	Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology	101	270-282	2023	
79)	Atsukawa M, Tsubota A, Kondo C, Shioda-Koyano K, Ishikawa T, <u>Toyoda H</u> , Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamura M, Iwasa M, Tanaka Y, Hatano M, Iwakiri K	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective multicenter study.	Hepatol Int	17	139-149	2023	
80)	Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, Atsukawa M, Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouse K, Tsutsui A, Ohama A, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y	New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study.	Cancer Med	12	6980-6993	2023	
81)	Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada K, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Eur J Cancer	180	9-20	2023	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
82)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Noritomo S, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y	Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancer Med	12	7772-7783	2023	
83)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology	101	283-291	2023	
84)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Letter: rising incidence and poor survival in patients with nonviral HCC – better HCC surveillance and treatment for alcohol-associated and non-alcohol fatty liver diseases are needed. authors' reply.	Aliment Pharmacol Ther	57	363-364	2023	
85)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.	J Cancer Res Clin Oncol	149	5591-5602	2023	
86)	Seko Y, Takahashi H, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study.	Hepatol Res	53	312-321	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Fujii H, Fujii M, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita M, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD.	Hepatol Res	53	391-400	2023	
88)	Watanabe M, <u>Toyoda H</u> , Kawabata T	Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by fully automated genetic analyzer $\mu$ TAS Wako g1.	PLoS ONE	18	e0278143	2023	
89)	Ishiba H, Sumida Y, Kamada Y, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.	J Gastroenterol Hepatol	38	896-904	2023	
90)	Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, Ikegami T, Fujii H, <u>Toyoda H</u> , Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.	Hepatol Res	53	489-496	2023	
91)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Comparison between atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma in patients with Child-Pugh class B in real-world clinical settings.	Oncology	101	542-552	2023	
92)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A	Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib versus sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients.	J Cancer Res Clin Oncol	149	7565-7577	2023	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
93)	Hiraoka A, Kumada T, Tada T, <u>Toyoda H</u> , Kariyama K, Hatanaka T, Kakizaki S, Naganuma A, Itobayashi E, Tsuji K, Ishikawa T, Ohama H, Tada F, Nouse K	Attempt to establish prognostic predictive system for hepatocellular carcinoma using artificial intelligence for assistance with selection of treatment modality.	Liver Cancer	25	565-575	2023	
94)	<u>Toyoda H</u>	Low surveillance receipt in cirrhotic patients with cured HCV: where are the barriers?	Liver Int	43	962-963	2023	○
95)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A	Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: how does adherence to the IMbrave150 trial inclusion criteria impact prognosis?	Target Oncol	18	221-233	2023	
96)	Yamauchi R., Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwaomto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, <u>Toyoda H</u> , Kanto T.	Serum osteopontin as a predictive biomarker for the response to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.	J Gastroenterol	58	565-574	2023	
97)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Tanaka T, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: a multicenter analysis.	Hepatol Res	53	737-748	2023	
98)	Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, <u>Toyoda H</u> , Yu ML, Nguyen MH	Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic hepatitis B patients in the indeterminate phase.	Hepatology	78	1558-1568	2023	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
99)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Hepatol Res	53	1031-1042	2023	
100)	Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguch T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Ueda S, Nakajima A, Sumida Y, Okanoue T	Association of serum albumin levels and long-term prognosis in patients with biopsy-confirmed nonalcoholic fatty liver disease.	Nutrients	15	2014	2023	
101)	Yamamoto T, Mizuno K, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Ishikawa T, Kanamori A, Yasuda S, <u>Toyoda H</u> , Yokota K, Hase T, Nishio N, Maeda O, Ishii M, Sone M, Ando Y, Akiyama M, Ishigami M, Kawashima H	Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.	Invest New Drugs	41	512-521	2023	
102)	Imajo K, Saigusa Y, Kobayashi T, Nagai K, Nishida S, Kawamura N, Doi H, Iwaki M, Nogami A, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Yasuda S, <u>Toyoda H</u> , Hayashi H, Kokubu S, Utsunomiya D, Takahashi H, Aishima S, Kim BK, Tamaki N, Saito S, Yoneda M, Loomba R, Nakajima A	M-PAST score is better than MAST score for the diagnosis of active fibrotic NASH.	Hepatol Res	53	844-856	2023	
103)	<u>Toyoda H</u> , Kikuchi K	Management of dialysis patients with HCV in the era of direct-acting antiviral therapy.	Ther Apher Dial	27	831-838	2023	○
104)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y	Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.	J Gastroenterol Hepatol	38	1389-1397	2023	
105)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y	Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function.	Oncology	101	624-633	2023	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
106)	Hatanaka T, Kakizaki S, Hiraoka A, Toyoda H, Kumada T	Reply to: "Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFTY, mALF and beyond".	Hepatol Int	17	1320-1321	2023	
107)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Solda C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A	Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.	Eur J Cancer	189	112933	2023	
108)	Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH	Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.	Hepatol Int	17	1150-1161	2023	○
109)	Hamill V, Wong S, Benselin J, Kraiden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velasquez Garcia HA, Yeung A, Johnson P, Barclay ST, Alvarez M, Toyoda H, Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson P, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha IN, Irving WL, Janjua NZ, Innes H	Mortality rates among patients achieving a hepatitis C cure in the interferon-free treatment era: data from three population cohorts.	Br Med J	382	e074001	2023	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
110)	Tada F, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.	J Gastroenterol	58	1134-1143	2023	
111)	Kuroda H, Oguri T, Kamiyama N, <u>Toyoda H</u> , Yasuda S, Imajo K, Suzuki Y, Sugimoto K, Akita T, Tanaka J, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Fujiwara Y, Abe T, Kakisaka K, Matsumoto T, Kumada T	Multivariable quantitative US parameters for assessing hepatic steatosis.	Radiology	309	e230341	2023	
112)	<u>Toyoda H</u> , Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Validation of noninvasive markers for HCC risk stratification in 1,389 patients with biopsy-proven NAFLD.	Gastro Hep Adv	2	1093-1102	2023	
113)	Nouse K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, Atsukawa M, Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Hatanaka T, Fukunishi S, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Iijima H, Matono T, Shimada N, Yasuda S, <u>Toyoda H</u> , Kumada T	Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.	Cancer Med	12	17849-17855	2023	
114)	Ito T, Morooka H, Takahashi H, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ishigami M, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T for the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Identification of clinical phenotypes associated with poor prognosis in patients with NAFLD via unsupervised machine learning.	J Gastroenterol Hepatol	38	1832-1839	2023	
115)	Nouse K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, Atsukawa M, Tani J, Tada T, Matsuo Y, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Hatanaka T, Fukunishi S, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yasuda S, <u>Toyoda H</u> , Kumada T	Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.	Liver Cancer Int	4	101-108	2023	
116)	Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, Kim HL, Arai T, Atsukawa M, Kawanaka M, <u>Toyoda H</u> , Ishigami M, Yu ML, Jun DW, Nguyen MH	Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease.	JAMA Netw Open	6	e2329568	2023	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
117) Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Usefulness of tumor marker score for prediction of prognosis in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.	Cancers	15	4348	2023	
118) Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyotou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima H, Sakamoto K, Ito K, Nishina S, Hino K, <u>Toyoda H</u> , Yatsuhashi H, Kage M, Mizokami M	New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.	J Gastroenterol	58	1252-1260	2023	
119) Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T	Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: a mixed-effects regression model approach.	Cancer Med	12	21680-21693	2023	
120) Yoshida Y, Ito A, Eto H, Suzuki A, Abe T, Kakisaka K, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Matsumoto T, Takahashi M, Okamoto H	Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	Hepatol Res.	54	24-31	2024	
121) <u>Miyasaka A</u> , Yoshida Y, Suzuki A, Endo K, Kakisaka K, Oikawa T, Abe T, Obara W, Matumoto T	Current elimination status of hepatitis C virus-infected maintenance hemodialysis patients in Iwate Prefecture, Japan	Ther Apher Dial	27	848-854	2023	○
122) Kakisaka K, Kuroda H, Abe T, Nakaya I, Watanabe T, Yusa K, Sato H, Suzuki A, Kooka Y, Endo K, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Matumoto T	Coincidental items in the definition of metabolic dysfunction-associated fatty liver are useful in identifying patients having significant fibrosis with fatty liver.	Hepatol Res.	53	857-865	2023	
123) Kishimoto K, Kakisaka K, Abe T, Ito A, Yusa K, Suzuki A, Endo K, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Sato A, Nishiya M, Yanagawa N, Kuroda H, Matsumoto T	A Case of Autoimmune Hepatitis Complicated by Undiagnosed Factor VII Deficiency: A Pitfall of Coagulopathy	Intern Med.		doi: 10.2169/internalmedicine.2854-23.	2023	
124) Yamamoto M, Terashima T, Yamashita T, Seki A, Nakagawa H, Nio K, <u>Shimakami T</u> , Takatori H, Arai K, Mizukoshi E, Honda M, Takeuchi S, Yamashita T.	Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.	Hepatol Res.			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
125)	Hayashi T, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Yamashita T.	Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab~Different Clinical Course in the Colon and Gastroduodenal Lesions~.	Intern Med.			in press	
126)	Miyazawa M, Yanagi M, Chiba T, Kido H, Matsuo T, Nishitani M, Orita N, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Terashima T, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Arai K, Yamashita T, Mizukoshi E, Honda M, Yamashita T.	Post-allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host Disease: A Case Report.	Intern Med.			in press	
127)	Shimizu R, Murai K, Tanaka K, Sato Y, Takeda N, Nakasyo S, Shirasaki T, Kawaguchi K, <u>Shimakami T</u> , Nio K, Nakaya Y, Kagiwada H, Horimoto K, Mizokami M, Kaneko S, Murata K, Yamashita T, Honda M.	Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes.	Hepatology Commun.	8(1)	e0351	2024	
128)	Hayashi T, Hayashi K, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Yamashita T.	Photodynamic therapy with talaporfin sodium for endoscopically unresectable gastric cancer using a novel simultaneous light-emitting method.	DEN Open.	4(1)	e334	2024	
129)	Shirasaki T, Murai K, Ishida A, Kuroki K, Kawaguchi K, Wang Y, Yamanaka S, Yasukawa R, Kawasaki N, Li YY, <u>Shimakami T</u> , Sumiyadorj A, Nio K, Sugimoto S, Orita N, Takayama H, Okada H, Thi Bich PD, Iwabuchi S, Hashimoto S, Ide M, Tabata N, Ito S, Matsushima K, Yanagawa H, Yamashita T, Kaneko S, Honda M.	Functional involvement of endothelial lipase in hepatitis B virus infection.	Hepatology Commun.	7(9)	e0206	2023	
130)	Orita N, Kawaguchi K, Honda M, Shimode T, Hayakawa N, Terashima T, Komura T, Nishikawa M, Horii R, Nio K, <u>Shimakami T</u> , Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S, Kagaya T, Yamashita T.	Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.	Biochemistry Biophysical Research Communications.	674	133-139	2023	
131)	Doan PTB, Nio K, <u>Shimakami T</u> , Kuroki K, Li YY, Sugimoto S, Takayama H, Okada H, Kaneko S, Honda M, Yamashita T.	Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors.	Viruses.	15(5)	1178	2023	
132)	Suda T, Takatori H, Hayashi T, Kaji K, Nio K, Terashima T, <u>Shimakami T</u> , Arai K, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Yamashita T.	Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis.	International Journal of Molecular Sciences.	24(9)	7732	2023	
133)	出島彰宏, 島上哲朗, 寺島健志, 堀井里和, 山田真也, 丹尾幸樹, 鷹取元, 荒井邦明, 山下竜也, 本多政夫, 金子周一, 山下太郎.	オンラインツールを用いた指定医療機関拡充によるC型慢性肝疾患患者への治療導入の促進	肝臓			in press	
134)	Toyoda H, <u>Kikuchi K</u>	Authors response to Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.	Therapeutic Apheresis and Dialysis.	28(1)	160-161	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
135)	<u>Kikuchi K</u> , et al.	Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic	Ther Apher Dial.	27(6)	1064-1069	2023	
136)	Hashiba T, <u>Kikuchi K</u> , et al	Infection prevention measures for patients on hemodialysis during COVID-19 pandemic in Japan: a nationwide questionnaire follow-up survey in 2022	Renal Replacement Therapy			2023	
137)	Toyoda H, <u>Kikuchi K</u> .	Management of dialysis patients with HCV in the era of direct-acting antiviral therapy	Ther Apher Dial.	27(5)	831-838	2023	○
138)	Toda M, <u>Kikuchi K</u> , et al	Cellular and Humoral Immune Responses after Breakthrough Infection in Patients Undergoing Hemodialysis	Vaccines			2023	
139)	Murakami M, <u>Kikuchi K</u> , et al	Association of four types of vascular access including arterial superficialization with mortality in maintenance hemodialysis patients: a nationwide cohort study in Japan	Am J Nephrol	54(3-4)	83-94	2023	
140)	Katagiri D, <u>Kikuchi K</u>	The Impact and Treatment of COVID-19 in Hemodialysis Patients	J Clin Med			2023	
141)	Yoshifuji A, <u>Kikuchi K</u> , et al	T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis	Vaccines			2023	
142)	Miyazaki T, Ueda H, <u>Ikegami T</u> , Honda A	Upregulation of taurine biosynthesis and bile acid conjugation with taurine through FXR in a mouse model with human-like bile acid composition	Metabolites	13(7)	824	2023	
143)	Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).	Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications	Clin Gastroenterol Hepatol	Online ahead of print.		2023	
144)	Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, <u>Ikegami T</u> , Fujii H, Toyoda H, Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanoue T, Nakajima A, Takahashi H; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).	Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease	Hepatol Res	53(6)	489-496	2023	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
145)	Sato M, Akamatsu M, Shima T, <u>Ikegami T</u> , Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, Koike K.	Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial	Am J Gastroenterol	118(8)	1365-1372	2023	
146)	Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, <u>Ikegami T</u> , Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K.	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study	Hepatol Int	17(1)	139-149	2023	
147)	柿崎文郎, 岩本淳一, 門馬匡邦, 玉虫惇, 上田元, 小西直樹, 屋良昭一郎, 宮崎照雄, 池上正, 本多彰	西欧食による腸内細菌叢と胆汁酸代謝への影響	消化と吸収	45(2)	119-122	2023	
148)	<u>Atsukawa M</u> , Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, <u>Ikegami T</u> , Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K.	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.	Hepatol Int.	Feb;17(1)	139-149.	2023	